Changes in systemic AKT activity might result from changes in the production or secretion of ILPs, changes in the expression of molecules that bind ILPs in the extracellular space and prevent them from signalling, or changes in the inherent ability of peripheral tissues to respond to ILPs (‘insulin resistance’). This evidence concerns the gene AKT1 and Insulin resistance.